ReviewCardiovascular diabetology2024
SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives.
Review in Cardiovascular diabetology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes.Diabetes, obesity & metabolism · 2025Trial
- Weight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes.Cardiovascular diabetology · 2025Trial
- Coronary flow reserve increase after 4-year dapagliflozin treatment in patients with type 2 diabetes: the DAPAHEART follow-up study.Cardiovascular diabetology · 2025Trial
- Cardiometabolic Aging Driven by Multi-Organ Crosstalk: Mechanisms and Therapeutic Strategies.International journal of molecular sciences · 2026Review
- Differential Therapeutic Modulations of Adiponectin: Beneficial, Adverse, and Context-Dependent Effects in Chronic Coronary Syndromes.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2026Review
- Cardiometabolic associations of SGLT-2 inhibitors on epicardial adiposity and left ventricular function in type 2 diabetes mellitus with coronary artery disease: insights from Malaysian EpiCAD study.Scientific reports · 2026Article
- Comparison of renal outcomes between sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist in Japanese patients with type 2 diabetes and obesity.Clinical and experimental nephrology · 2026Article
- MARCH1 Deletion Attenuates HFpEF by Promoting Adipose Beiging.Comprehensive Physiology · 2026Article
- Oxidative Stress in Diabetic Cardiomyopathy: Molecular Mechanisms and Emerging Therapeutic Targets.Biomolecules · 2026Review
- Illuminating Glucose: How to Unveil Organ-Specific Insulin Resistance and Guide Metabolic Strategies in Diabetes.Diabetes/metabolism research and reviews · 2026Review
- From bench to bedside: adipose tissue fibrosis in obesity, anti-diabetic therapies, and bariatric surgery.The Korean journal of internal medicine · 2026Review
- Epicardial Adipose Tissue Volume and Left Atrial Remodeling: A J-Shaped Association in Older Adults.Journal of cardiovascular development and disease · 2026Article
- Heart matters: How glucose- and lipid-modulating drugs remodel epicardial adipose tissue accumulation, inflammatory patterns and browning.Diabetes, obesity & metabolism · 2026Review
- Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations.Frontiers in cardiovascular medicine · 2026Review
- The Potential Role of SGLT2 Inhibitors in the Treatment of Depression: Mechanisms and Clinical Prospects.Drug design, development and therapy · 2026Review
- Review
- Targeting Neurodegeneration with SGLT2is: From Molecular Mechanisms to Clinical Implications.Molecular neurobiology · 2025Review
- Rethinking the Diabetes-Cardiovascular Disease Continuum: Toward Integrated Care.Journal of clinical medicine · 2025Article
- Beyond Traditional Risk Factors: Integrating Epicardial Adipose Tissue into the Comorbidity Landscape of HFpEF.Journal of clinical medicine · 2025Review
- Advances and challenges of targeting epicardial adipose tissue (EAT) and perivascular adipose tissue (PVAT).Cardiovascular diabetology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as important agents for the treatment of type 2 diabetes mellitus (T2DM). SGLT2 inhibitors have been associated with improved cardiovascular outcomes, not only through their immediate hemodynamic effects-such as glycosuria and (at least temporary) increased natriuresis-but also due to their multifaceted impact on metabolism. Recently, studies have also focused on the effects of SGLT2 inhibitors on adipose tissue. Aside from the well-documented effects on human adiposity, SGLT2i have shown, both in vitro and in murine models, the ability to reduce fat mass, upregulate genes related to browning of white adipose tissue, influence adipocyte size and fatty acid oxidation, and improve oxidative stress and overall metabolic health. In humans, even though data are still limited, recent evidence seems to confirm that the SGLT2i effects observed in cardiovascular outcome trials could be partially explained by their impact on adipose tissue. This review aims to clarify the impact of SGLT2i on adipose tissue, highlighting their role in metabolic health and their potential to transform treatment strategies for T2DM beyond glucose metabolism.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.